Revolade drug company Novartis is approved in Russia for use in children over 6 years with a diagnosis of idiopathic thrombocytopenic purpura

For citations:

Revolade drug company Novartis is approved in Russia for use in children over 6 years with a diagnosis of idiopathic thrombocytopenic purpura. Russian Journal of Pediatric Hematology and Oncology. 2017;4(2):120-121. (In Russ.)